This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Description of the Association of Signs and Symptoms Present at Acromegaly Diagnosis (ACRO-POLIS)

This study has been completed.
Information provided by (Responsible Party):
Ipsen Identifier:
First received: November 28, 2013
Last updated: July 28, 2014
Last verified: July 2014
The purpose of this study is to describe most characteristic association of signs and symptoms present at the time of acromegaly diagnosis.


Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Description of the Associations of Sign-and-symptom at Acromegaly Diagnosis.

Resource links provided by NLM:

Further study details as provided by Ipsen:

Primary Outcome Measures:
  • Description of the most characteristic sign-and-symptom associations of acromegaly, collected by a patient questionnaire. [ Time Frame: At the time of patient diagnosis, up to 3 months ]

Secondary Outcome Measures:
  • Description of demographic and clinical characteristics of patients with acromegaly, collected by a patient questionnaire. [ Time Frame: At the time of patient diagnosis, up to 3 months ]

Enrollment: 648
Study Start Date: September 2013
Study Completion Date: June 2014
Primary Completion Date: June 2014 (Final data collection date for primary outcome measure)
Acromegalic patients


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Acromegalic patients

Inclusion Criteria:

  • Adult patient (greater than or equal to 18 years old)
  • Patient with acromegaly, diagnosed for less than 5 years

Exclusion Criteria:

  • Patient who have objected to the collection of his/her data
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02012127

Hôpital Sud
Amiens, France
CHU Besançon Hôpital Jean Minjoz
Besançon, France
Hôpital la Cavale Blanche
Brest, France
Chu Cote de Nacre
Caen, France
Hôpital Henri Mondor
Creteil, France
Chu de Grenoble Hôpital Albert Michallon
Grenoble, France
Hôpital Claude Huriez
Lille, France
Hôpital le Cluzeau
Limoges, France
Hôpital Neuro-cardiologique
Lyon, France
Hôpital de la Timone
Marseille, France
Hôpital Lepeyronie
Montpellier, France
Hôpitaux de Brabois
Nancy, France
CHR Orléans - Hôpital la Source
Orléans, France
CH de Bicetre
Paris, France
CH Pitie Salpetreire
Paris, France
Hôpital Lariboisiere
Paris, France
Hôpital Haut Leveque
Pessac, France
CHU Reims - Hôpital Robert Debre
Reims, France
Hôpital Sud Anne de Bretagne
Rennes, France
CHU Rouen - Hôpital de Bois Guillaume
Rouen, France
Hôptital Nord
Saint Etienne, France
Hôpital Civil
Strasbourg, France
Hôpital de Hautepierre
Strasbourg, France
Hôpital Larrey
Toulouse, France
CHU Bretonneau
Tours, France
Sponsors and Collaborators
Study Director: Karima Menia, PhD Ipsen
  More Information

Responsible Party: Ipsen Identifier: NCT02012127     History of Changes
Other Study ID Numbers: 8-54-52030-266
Study First Received: November 28, 2013
Last Updated: July 28, 2014

Additional relevant MeSH terms:
Signs and Symptoms
Bone Diseases, Endocrine
Bone Diseases
Musculoskeletal Diseases
Pituitary Diseases
Hypothalamic Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Endocrine System Diseases processed this record on September 21, 2017